KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Share-based Compensation: 2010-2024

Historic Share-based Compensation for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $27.8 million.

  • Supernus Pharmaceuticals' Share-based Compensation rose 1.97% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 16.80%. This contributed to the annual value of $27.8 million for FY2024, which is 3.72% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Share-based Compensation stood at $27.8 million for FY2024, which was up 3.72% from $26.8 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Share-based Compensation peaked at $27.8 million during FY2024, and registered a low of $16.6 million during FY2020.
  • In the last 3 years, Supernus Pharmaceuticals' Share-based Compensation had a median value of $26.8 million in 2023 and averaged $24.0 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 1.91% in 2022, then skyrocketed by 52.32% in 2023.
  • Supernus Pharmaceuticals' Share-based Compensation (Yearly) stood at $16.6 million in 2020, then increased by 8.15% to $17.9 million in 2021, then declined by 1.91% to $17.6 million in 2022, then spiked by 52.32% to $26.8 million in 2023, then grew by 3.72% to $27.8 million in 2024.